Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websitecytomx.com
CategoryBioTech
Phone(805) 964-9700
Employees
Founded2008

Offices

Santa Barbara, USA
460 Ward Drive
Suite E1
Santa Barbara, CA, 93111
USA

People

CEO & Board of Directors
CFO
VP, Business Development & Alliance Management
Board Member
Board of Directors
Board of Directors
Board of Directors
Board of Directors
Show All People

Funding

TOTAL $43.5M
FUNDING TOTAL $43.5M
Convertible Note, 3/2010
$2.5M
Series B, 9/2010
Third Rock Ventures
Roche Venture Fund
$30M
Series B, 7/2012
Canaan Partners
Third Rock Ventures
$11M

Tags

CytomX Therapeutics

CytomX Therapeutics is an early stage, privately-funded biotechnology company developing Probodiesâ„¢, proteolytically-activated antibodies. Probodies, by their ability to site-direct the activity of antibodies, will result in an improved therapeutic index for validated targets as well enable the drugging of targets with broad tissue expression. Our mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.

Recent Milestones

Videos

Screenshots

Sources

  1. SEC (sec.gov) [edit]
  2. CytomX Therapeutics Completes $30M Series B Financing (finsmes.com) [edit]
  3. Drug developer CytomX expands Series B by $11 million, looks to make key hires (bizjournals.com) [edit]
  4. Pfizer turns to upstart CytomX for $635M deal on armed antibody tech Read more: Pfizer turns to upstart CytomX for $635M deal on armed antibody tech - FierceBiotech http://www.fiercebiotech.com/story/pfizer-turns-upstart-cytomx-635m-deal-armed-antibody-t (fiercebiotech.com) [edit]
Edit This Page
Last Edited 12/19/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy